• Molecular NamePirenzepine
  • SynonymNA
  • Weight351.41
  • Drugbank_IDDB00670
  • ACS_NO28797-61-7
  • Show 2D model
  • LogP (experiment)0.413
  • LogP (predicted, AB/LogP v2.0)0.31
  • pka2.1, 8.1
  • LogD (pH=7, predicted)-0.82
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.8
  • LogSw (predicted, AB/LogsW2.0)3.62
  • Sw (mg/ml) (predicted, ACD/Labs)1.72
  • No.of HBond Donors1
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds2
  • TPSA68.78
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyUsed in the treatment of peptic ulcers, as it reduces gastric acid secretion and reduces muscle spasm. It is in a class of drugs known as muscarinic receptor antagonists - acetylcholine being the neurotransmitter of the parasympathetic nervous system which initiates the rest-and-digest state (as opposed to fight-or-flight), the result being an increase in gastric motility and digestion. It has no effects on the brain and spinal cord as it cannot diffuse through the blood-brain barrier.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability14.0
  • Protein binding10.0
  • Volume of distribution (VD)0.2 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half life11 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A